Somewhat Positive News Coverage Somewhat Unlikely to Impact Perrigo Company plc (PRGO) Stock Price
Press coverage about Perrigo Company plc (NYSE:PRGO) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Perrigo Company plc earned a news impact score of 0.16 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.8603529510952 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Perrigo Company plc (PRGO) PT Raised to $107.00 at Cantor Fitzgerald (americanbankingnews.com)
- Starboard likes Perrigo, undervalued despite strong OTC business; shares up 4% (seekingalpha.com)
- Starboard Value CEO Smith pushes Perrigo, Altaba as best ideas (cnbc.com)
- Perrigo CEO: Amazon a “natural player” in OTC drug market (mibiz.com)
A number of research analysts have weighed in on PRGO shares. CIBC started coverage on shares of Perrigo Company plc in a research note on Thursday, September 7th. They issued an “outperform” rating and a $88.00 price target on the stock. Jefferies Group LLC reaffirmed a “hold” rating and issued a $71.00 price target on shares of Perrigo Company plc in a research note on Wednesday, May 24th. Royal Bank Of Canada lifted their price target on shares of Perrigo Company plc from $60.00 to $64.00 and gave the company an “underperform” rating in a research note on Friday, August 11th. Canaccord Genuity set a $86.00 price target on shares of Perrigo Company plc and gave the company a “buy” rating in a research note on Monday, May 22nd. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and issued a $68.00 price target on shares of Perrigo Company plc in a research note on Wednesday, May 31st. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $88.00.
Perrigo Company plc (PRGO) traded up 4.63% during trading on Tuesday, hitting $89.01. 4,135,870 shares of the company’s stock traded hands. Perrigo Company plc has a 52-week low of $63.68 and a 52-week high of $99.14. The company’s 50 day moving average price is $76.16 and its 200 day moving average price is $72.96. The company’s market cap is $12.69 billion.
Perrigo Company plc (NYSE:PRGO) last announced its earnings results on Thursday, August 10th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.28. Perrigo Company plc had a positive return on equity of 11.55% and a negative net margin of 51.04%. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same period last year, the firm posted $1.93 EPS. The business’s revenue was down 7.7% compared to the same quarter last year. Analysts expect that Perrigo Company plc will post $4.58 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Friday, August 25th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.72%. The ex-dividend date is Wednesday, August 23rd. Perrigo Company plc’s dividend payout ratio is presently -3.51%.
In other news, EVP Thomas Farrington sold 865 shares of the firm’s stock in a transaction on Friday, August 18th. The stock was sold at an average price of $78.40, for a total transaction of $67,816.00. Following the completion of the sale, the executive vice president now directly owns 2,870 shares of the company’s stock, valued at approximately $225,008. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Sharon Kochan sold 318 shares of the firm’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $81.36, for a total value of $25,872.48. Following the sale, the executive vice president now directly owns 10,231 shares of the company’s stock, valued at $832,394.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,299 shares of company stock valued at $259,604. Insiders own 6.90% of the company’s stock.
About Perrigo Company plc
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Stock Ratings for Perrigo Company plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company plc and related stocks with our FREE daily email newsletter.